Indications
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Composition
- Active substance
- rivastigmine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rivastigmine Sandoz
- Active substance
- rivastigmine
- ATC code
- N06DA03
- Group
- Nervous system
- Therapeutic area
- Dementia, Alzheimer Disease, Parkinson Disease
- Marketing authorisation holder
- Sandoz GmbH
- Status
- Authorised
- EU authorisation